Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych |

Communication of the President of the Office of 1 September 2022 on the recommendation of the European Medicines Agency (EMA) for approval of the first adapted COVID-19 booster vaccines in the European Union.

01/09/2022
Global regulators call for international collaboration to integrate real-world evidence into regulatory decision-making.

25/07/2022
Communication of the President of the Office of 22 July 2022 on the recommendations for restrictions on the use of the cancer medicine Rubraca by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

22/07/2022
Communication of the President of the Office of 22 July 2022 on the recommendation to extend the indication for Imvanex smallpox vaccine to include protection of adults against monkeypox by the CHMP and the EMA.

22/07/2022
Communication from the President of the Office of 1 July 2022 on a meeting of global regulatory authorities (EMA, FDA, ICMRA) to discuss emerging evidence in support of adaptation of COVID-19 vaccines in relation to virus evolution.

07/07/2022
Communication of the President of the Office of 28 June 2022 on the review of the European Medicines Agency's data on the extended coverage of Imvanex smallpox vaccine to protect humans against monkeypox

01/07/2022
It is with the greatest sadness to inform you that our dear colleague, URPL,WMiPB long-time employee Lidia Retkowska-Mika has passed away.

08/05/2020